Post-approval studies (Phase 4)Study completedNCT04662931
What this trial is testing
An Indian Multi-centric Phase IV Study to Assess the Safety of Crizanlizumab in Sickle Cell Disease Patients
Who this might be right for
Sickle Cell Disease (SCD)
Novartis Pharmaceuticals 140